Related Experiment Video

Updated: Jan 1, 2026

Retinal Pathophysiological Evaluation in a Rat Model
09:11

Retinal Pathophysiological Evaluation in a Rat Model

Published on: May 6, 2022

5.1K

How and why SGLT2 inhibitors should be explored as potential treatment option in diabetic retinopathy: clinical

Marcus May1, Theodor Framke2, Bernd Junker3

  • 1Hannover Medical School, MHH CRC Core Facility, Feodor-Lynen-Strasse 15, Hannover, 30625, Germany.

Therapeutic Advances in Endocrinology and Metabolism
|December 20, 2019
PubMed

Insights

Sodium-glucose cotransporter 2 (SGLT2) inhibitors may offer a novel treatment for diabetic microangiopathy. Further clinical trials are necessary to confirm their role in preventing complications like retinopathy, neuropathy, and nephropathy.

Area of Science:

  • Endocrinology
  • Nephrology
  • Ophthalmology

Background:

  • Type 2 diabetes patients face high risks of microvascular complications (retinopathy, neuropathy, nephropathy).
  • Current management (glucose, blood pressure, cholesterol control) is insufficient for preventing diabetic microangiopathy.
  • Effective pharmacological treatments for diabetic microangiopathy remain limited.

Purpose of the Study:

  • To explore the potential of sodium-glucose cotransporter 2 (SGLT2) inhibition in preventing diabetic microangiopathy.
  • To assess SGLT2 inhibitors as a direct protective strategy against microvascular complications.

Main Methods:

  • This study proposes the need for randomized controlled clinical trials.
  • Focus on proof-of-concept investigations for SGLT2 inhibitor efficacy.

Main Results:

  • The potential protective effects of SGLT2 inhibition against microvascular complications are hypothesized.
  • Further research is required to validate these findings.

Conclusions:

  • SGLT2 inhibitors show promise for treating and preventing diabetic microangiopathy.
  • Clinical trials are essential to establish the role of SGLT2 inhibitors in managing diabetic complications.
Keywords:
SGLT2 Inhibitionacademiadiabetes mellitusdiabetic macula edemadiabetic retinopathymethodspharmacologytrial design

More Related Videos

Studying Diabetes Through the Eyes of a Fish: Microdissection, Visualization, and Analysis of the Adult tgfli:EGFP Zebrafish Retinal Vasculature10:07

Studying Diabetes Through the Eyes of a Fish: Microdissection, Visualization, and Analysis of the Adult tgfli:EGFP Zebrafish Retinal Vasculature

Published on: December 26, 2017

13.9K
Trypsin Digest Protocol to Analyze the Retinal Vasculature of a Mouse Model09:03

Trypsin Digest Protocol to Analyze the Retinal Vasculature of a Mouse Model

Published on: June 13, 2013

19.0K

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
783
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
542
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
519